gadobenate dimeglumine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
diagnostic agents, gadolinium derivatives	4471	127000-20-8

Description:

Molecule	Description
Synonyms: multihance gadobenate dimeglumine	Molecular weight: 1058.16 Formula: C36H62GdN5O21 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

multihance
gadobenate dimeglumine

Molecular weight: 1058.16
Formula: C36H62GdN5O21
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Nov. 23, 2004	FDA	BRACCO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	556.70	52.62	120	4954	4202	50595848
Hypersensitivity	362.12	52.62	239	4835	214922	50385128
Contrast media reaction	298.24	52.62	56	5018	951	50599099
Urticaria	287.84	52.62	172	4902	129389	50470661
Skin hypertrophy	251.26	52.62	59	5015	3036	50597014
Anaphylactic reaction	236.79	52.62	113	4961	53942	50546108
Skin induration	223.26	52.62	53	5021	2858	50597192
Anaphylactoid reaction	199.91	52.62	50	5024	3356	50596694
Skin tightness	199.86	52.62	51	5023	3712	50596338
Sneezing	174.43	52.62	62	5012	13982	50586068
Pruritus	151.88	52.62	163	4911	283405	50316645
Vomiting	149.20	52.62	205	4869	460553	50139497
Skin fibrosis	139.93	52.62	29	5045	830	50599220
Erythema	137.40	52.62	115	4959	146299	50453751
Fibrosis	124.20	52.62	35	5039	3712	50596338
Nausea	120.63	52.62	235	4839	705163	49894887
Throat tightness	89.28	52.62	43	5031	20804	50579246
Throat irritation	85.05	52.62	47	5027	30192	50569858
Feeling hot	83.86	52.62	51	5023	39151	50560899
Skin hyperpigmentation	75.86	52.62	26	5048	5250	50594800
Dyspnoea	74.93	52.62	167	4907	547441	50052609
Gadolinium deposition disease	71.28	52.62	11	5063	51	50599999
Joint contracture	70.94	52.62	19	5055	1665	50598385
Joint range of motion decreased	69.75	52.62	35	5039	18477	50581573
Foaming at mouth	68.75	52.62	17	5057	1085	50598965
Peau d'orange	68.54	52.62	12	5062	134	50599916
Emotional distress	68.34	52.62	40	5034	28623	50571427
Scar	68.21	52.62	30	5044	11788	50588262
Anaphylactic shock	66.94	52.62	35	5039	20120	50579930
Contrast media allergy	62.94	52.62	18	5056	2009	50598041
Anhedonia	57.64	52.62	25	5049	9499	50590551
Drug ineffective	56.07	52.62	8	5066	819325	49780725
Skin discolouration	56.00	52.62	37	5037	32720	50567330

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	379.50	56.07	87	3033	3855	29567552
Hypersensitivity	290.55	56.07	131	2989	52772	29518635
Urticaria	172.59	56.07	93	3027	54567	29516840
Vomiting	172.13	56.07	156	2964	212104	29359303
Anaphylactic reaction	165.96	56.07	73	3047	27500	29543907
Skin induration	158.79	56.07	38	3082	2016	29569391
Skin hypertrophy	157.90	56.07	39	3081	2364	29569043
Nausea	157.47	56.07	171	2949	289084	29282323
Sneezing	156.90	56.07	44	3076	4370	29567037
Anaphylactoid reaction	150.44	56.07	36	3084	1909	29569498
Skin tightness	144.93	56.07	35	3085	1929	29569478
Contrast media reaction	140.39	56.07	29	3091	776	29570631
Joint contracture	107.15	56.07	27	3093	1773	29569634
Fibrosis	95.23	56.07	26	3094	2333	29569074
Joint range of motion decreased	94.05	56.07	32	3088	6022	29565385
Skin fibrosis	90.20	56.07	21	3099	986	29570421
Scar	85.57	56.07	29	3091	5390	29566017
Anaphylactic shock	82.32	56.07	36	3084	13300	29558107
Pruritus	80.80	56.07	79	3041	116770	29454637
Extremity contracture	74.97	56.07	17	3103	709	29570698
Deformity	72.65	56.07	19	3101	1445	29569962
Emotional distress	56.17	56.07	28	3092	13867	29557540

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	576.39	65.25	131	6441	5761	64486399
Hypersensitivity	574.30	65.25	313	6259	196139	64296021
Anaphylactic reaction	378.19	65.25	169	6403	68495	64423665
Urticaria	361.99	65.25	210	6362	147107	64345053
Contrast media reaction	340.27	65.25	69	6503	1743	64490417
Anaphylactoid reaction	314.48	65.25	77	6495	4661	64487499
Skin hypertrophy	312.81	65.25	76	6496	4453	64487707
Skin induration	272.74	65.25	67	6505	4108	64488052
Sneezing	269.34	65.25	88	6484	15163	64476997
Skin tightness	266.17	65.25	68	6504	4893	64487267
Vomiting	244.84	65.25	289	6283	550828	63941332
Nausea	220.84	65.25	329	6243	785471	63706689
Pruritus	209.08	65.25	204	6368	312196	64179964
Skin fibrosis	172.92	65.25	38	6534	1421	64490739
Erythema	153.34	65.25	137	6435	186933	64305227
Fibrosis	137.37	65.25	40	6532	4688	64487472
Anaphylactic shock	133.33	65.25	64	6508	30264	64461896
Joint contracture	125.38	65.25	32	6540	2287	64489873
Joint range of motion decreased	117.07	65.25	51	6521	19292	64472868
Scar	103.40	65.25	42	6530	13356	64478804
Skin hyperpigmentation	96.47	65.25	33	6539	6518	64485642
Throat tightness	93.13	65.25	46	6526	23114	64469046
Gadolinium deposition disease	90.48	65.25	14	6558	65	64492095
Throat irritation	86.20	65.25	49	6523	32662	64459498
Feeling hot	85.69	65.25	55	6517	45608	64446552
Contrast media allergy	84.39	65.25	23	6549	2118	64490042
Peau d'orange	83.74	65.25	16	6556	293	64491867
Contrast media deposition	74.83	65.25	12	6560	73	64492087
Dyspnoea	70.36	65.25	195	6377	718479	63773681
Emotional distress	66.59	65.25	43	6529	35995	64456165

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D003287	Contrast Media
MeSH PA	D064907	Diagnostic Uses of Chemicals

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4032768	VUID
N0000188993	NUI
4032768	VANDF
CHEMBL1200571	ChEMBL_ID
C064572	MESH_SUPPLEMENTAL_RECORD_UI
3Q6PPC19PO	UNII
24838350	PUBCHEM_CID
68173	RXNORM
19178	MMSL
64278	MMSL
64293	MMSL
d05428	MMSL
007717	NDDF
414308003	SNOMEDCT_US
C0209453	UMLSCUI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
MultiHance	HUMAN PRESCRIPTION DRUG LABEL	1	0270-5164	INJECTION, SOLUTION	529 mg	INTRAVENOUS	NDA	28 sections
MultiHance	HUMAN PRESCRIPTION DRUG LABEL	1	0270-5264	INJECTION, SOLUTION	529 mg	INTRAVENOUS	NDA	27 sections